China Biologic Products to Report Third Quarter 2020 Financial Results
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) will release its third quarter 2020 financial results on November 24, 2020, after market close. Management will conduct a conference call to discuss these results on November 25, 2020, at 7:30 a.m. ET. The call can be accessed via specific dial-in numbers provided for various regions. Additionally, a replay will be available until December 2, 2020. China Biologic is recognized as a leading plasma-based biopharmaceutical company in China, manufacturing critical therapies for serious health conditions.
- Upcoming financial results announcement may indicate business performance.
- Strong product portfolio in critical therapies for medical emergencies.
- None.
BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2020 financial results on Tuesday, November 24, 2020 after the market closes.
The Company's management will hold a conference call at 7:30 a.m. ET on Wednesday, November 25, 2020, which is 8:30 p.m. Beijing Time on November 25, 2020, to discuss third quarter 2020 results. Listeners may access the call by dialing:
US: | 1 888 346 8982 |
International: | 1 412 902 4272 |
Hong Kong: | 800 905945 |
Mainland China: | 4001 201203 |
A telephone replay will be available one hour after the conclusion of the conference call through December 2, 2020. The dial-in details are:
US: | 1 877 344 7529 |
International: | 1 412 317 0088 |
Passcode: | 10149967 |
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
Contact:
China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com
The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
E-mail: phil@thefootegroup.com
View original content:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-third-quarter-2020-financial-results-301172617.html
SOURCE China Biologic Products Holdings, Inc.
FAQ
When will China Biologic Products report its third quarter 2020 financial results?
What time is the conference call to discuss the financial results for CBPO?
How can I access the conference call for CBPO?
Will there be a replay of the conference call for China Biologic Products?
